BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao D, Wagner AH, Fankhaenel S, Stojanovic T, Schweyer S, Panzner S, Hecker M. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut. 2005;54:70-77. [PMID: 15591506 DOI: 10.1136/gut.2003.029587] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen TX, Huang L, Gauthier M, Yang G, Wang Q. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine 2016;11:1169-85. [DOI: 10.2217/nnm.16.9] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 16.7] [Reference Citation Analysis]
2 Schmitz V, Dombrowski F, Prieto J, Qian C, Diehl L, Knolle P, Sauerbruch T, Caselmann WH, Spengler U, Leifeld L. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology. 2006;44:430-439. [PMID: 16871541 DOI: 10.1002/hep.21274] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
3 Marafini I, Monteleone G. Inflammatory bowel disease: new therapies from antisense oligonucleotides. Ann Med 2018;50:361-70. [PMID: 29911450 DOI: 10.1080/07853890.2018.1490025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 2009;60:994-1005. [DOI: 10.1002/art.24434] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
5 Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Methods Mol Biol. 2009;511:193-233. [PMID: 19347299 DOI: 10.1007/978-1-59745-447-6_9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
6 Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Perminow G, Reikvam DH, Lyckander LG, Brandtzaeg P, Vatn MH, Carlsen HS. Increased number and activation of colonic macrophages in pediatric patients with untreated Crohn's disease. Inflamm Bowel Dis 2009;15:1368-78. [PMID: 19322902 DOI: 10.1002/ibd.20916] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
8 Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, Hovanesian V, Monfils PR, Resnick M, Moss SF, Ramratnam B. Engineering mucosal RNA interference in vivo. Mol Ther 2006;14:336-42. [PMID: 16766229 DOI: 10.1016/j.ymthe.2006.04.001] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 4.3] [Reference Citation Analysis]
9 Blanco-Kelly F, Matesanz F, Alcina A, Teruel M, Díaz-Gallo LM, Gómez-García M, López-Nevot MA, Rodrigo L, Nieto A, Cardeña C, Alcain G, Díaz-Rubio M, de la Concha EG, Fernandez O, Arroyo R, Martín J, Urcelay E. CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility. PLoS One 2010;5:e11520. [PMID: 20634952 DOI: 10.1371/journal.pone.0011520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
10 Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends in Immunology 2009;30:165-72. [DOI: 10.1016/j.it.2009.01.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
11 Felix NJ, Suri A, Salter-cid L, Nadler SG, Gujrathi S, Corbo M, Aranda R. Targeting lymphocyte co-stimulation: From bench to bedside. Autoimmunity 2010;43:514-25. [DOI: 10.3109/08916931003674741] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
12 Wagner DH Jr. Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to Diabetogenesis. Front Endocrinol (Lausanne) 2017;8:208. [PMID: 28878738 DOI: 10.3389/fendo.2017.00208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
13 Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflamm Bowel Dis. 2006;12:1013-1024. [PMID: 17075342 DOI: 10.1097/01.mib.0000234135.43336.72] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
14 Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther 2012;342:850-60. [PMID: 22691298 DOI: 10.1124/jpet.112.192203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
15 Ocampo SM, Romero C, Aviñó A, Burgueño J, Gassull MA, Bermúdez J, Eritja R, Fernandez E, Perales JC. Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice. Mol Ther 2012;20:382-90. [PMID: 22044934 DOI: 10.1038/mt.2011.236] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
16 Arranz A, Reinsch C, Papadakis KA, Dieckmann A, Rauchhaus U, Androulidaki A, Zacharioudaki V, Margioris AN, Tsatsanis C, Panzner S. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2013;165:163-172. [PMID: 23178664 DOI: 10.1016/j.jconrel.2012.11.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
17 Dikopoulos N, Schmid RM, Bachem M, Buttenschoen K, Adler G, Chiang JY, Weidenbach H. Bile synthesis in rat models of inflammatory bowel diseases. Eur J Clin Invest 2007;37:222-30. [PMID: 17359490 DOI: 10.1111/j.1365-2362.2007.01779.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
18 Tsuji F, Setoguchi C, Okamoto M, Seki I, Sasano M, Aono H. Bucillamine inhibits CD40-mediated Akt activation and antibody production in mouse B-cell lymphoma. Int Immunopharmacol 2012;14:47-53. [PMID: 22735757 DOI: 10.1016/j.intimp.2012.06.012] [Reference Citation Analysis]
19 Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644-670. [PMID: 16481219 DOI: 10.1016/j.ymthe.2006.01.001] [Cited by in Crossref: 366] [Cited by in F6Publishing: 338] [Article Influence: 22.9] [Reference Citation Analysis]
20 Garciafigueroa Y, Trucco M, Giannoukakis N. A brief glimpse over the horizon for type 1 diabetes nanotherapeutics. Clin Immunol 2015;160:36-45. [PMID: 25817545 DOI: 10.1016/j.clim.2015.03.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
21 Mañé J, Lorén V, Pedrosa E, Ojanguren I, Domènech E, Gassull MA, Cabré E. Therapeutic effect of antisecretory factor-rich egg yolk on the late phases of 2,4,6-trinitrobenzenesulphonic acid colitis in mice. Br J Nutr 2011;106:1522-8. [PMID: 21733301 DOI: 10.1017/S0007114511002042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Marafini I, Di Fusco D, Calabrese E, Sedda S, Pallone F, Monteleone G. Antisense approach to inflammatory bowel disease: prospects and challenges. Drugs 2015;75:723-30. [PMID: 25911184 DOI: 10.1007/s40265-015-0391-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
23 Takedatsu H, Mitsuyama K, Torimura T. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11343-11352 [PMID: 26525603 DOI: 10.3748/wjg.v21.i40.11343] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
24 Liu DY, Xu R, Huang MF, Huang HY, Wang X, Zou Y, Yue HY, Zhao HM. Si Shen Wan Regulates Phospholipase Cγ-1 and PI3K/Akt Signal in Colonic Mucosa from Rats with Colitis. Evid Based Complement Alternat Med. 2015;2015:392405. [PMID: 26273312 DOI: 10.1155/2015/392405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
25 Stojanovic T, Scheele L, Wagner AH, Middel P, Bedke J, Lautenschläger I, Leister I, Panzner S, Hecker M. STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. Gene Ther 2007;14:883-90. [PMID: 17361215 DOI: 10.1038/sj.gt.3302931] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
26 Daub S, Lutgens E, Münzel T, Daiber A. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection. Int J Mol Sci 2020;21:E8533. [PMID: 33198327 DOI: 10.3390/ijms21228533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol. 2006;176:2617-2624. [PMID: 16456024 DOI: 10.4049/jimmunol.176.4.2617] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 6.4] [Reference Citation Analysis]
28 Salem AK, Behlke MA. SiRNA Delivery Vehicles. In: Johnson PH, editor. RNA Interference. Hoboken: John Wiley & Sons, Inc.; 2011. pp. 174-215. [DOI: 10.1002/9780470923733.ch6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Zhang XJ, Leung FP, Hsiao WW, Tan S, Li S, Xu HX, Sung JJ, Bian ZX. Proteome profiling of spinal cord and dorsal root ganglia in rats with trinitrobenzene sulfonic acid-induced colitis. World J Gastroenterol 2012; 18(23): 2914-2928 [PMID: 22736915 DOI: 10.3748/wjg.v18.i23.2914] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
30 Wagner AH, Conzelmann M, Fitzer F, Giese T, Gülow K, Falk CS, Krämer OH, Dietrich S, Hecker M, Luft T. JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter. Biochemical Pharmacology 2015;96:52-64. [DOI: 10.1016/j.bcp.2015.04.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hu Y, Wang F, Zhang D, Sun Q, Li W, Dai Y, Zhou M, Hang C. Expression of intestinal CD40 after experimental traumatic brain injury in rats. Journal of Surgical Research 2013;184:1022-7. [DOI: 10.1016/j.jss.2013.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
32 Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC. Application of liposomes in drug development--focus on gastroenterological targets. Int J Nanomedicine. 2013;8:1325-1334. [PMID: 23630417 DOI: 10.2147/ijn.s42153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]